Dr. Sonja Nicoll is a Senior Director at Amgen with over 15 years of experience in biologics development, process optimization, and technology transfer. Prior to joining Amgen, she held senior leadership roles at Horizon and Sandoz, where she led cross-functional teams and contributed to the development and regulatory submission of biosimilar and innovative drug products. With a strong scientific background in protein characterization and pharmaceutical formulation, Dr. Nicoll has worked across all phases of drug product development. She holds a Ph.D. in biochemistry and previously conducted postdoctoral research at The Ohio State University.

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes.